- In August 2024, Saridon, the renowned pain relief brand from Bayer's Consumer Health Division in India, has launched ‘Saridon Woman,’ a pioneering solution designed specifically for period pain. This innovative product offers comprehensive relief from common menstrual discomforts, including abdominal cramps, backaches, and headaches. Saridon Woman represents a significant advancement in the over-the-counter sector, uniquely combining the effectiveness of paracetamol with the plant-based compound hyoscine butylbromide to address menstrual pain
- In September 2023, Defender Pharmaceuticals announced that the Food and Drug Administration (FDA) has awarded priority review status to its new drug application for DPI-386 nasal gel, an intranasal formulation of scopolamine (also known as hyoscine). This gel aims to serve as a preventive treatment for motion sickness, offering a potentially more convenient option for patients
- In September 2022, the Indian Union Health and Family Welfare Minister revealed that hyoscine butylbromide was included in the National List of Essential Medicines 2022, which comprises 384 medications categorized into 27 distinct groups. This recognition underscores the drug’s importance in managing various medical conditions and highlights its role in enhancing healthcare access across the country
- In December 2020, Sanofi has introduced BuscoMint Peppermint Oil 0.2ml capsules for the treatment of irritable bowel syndrome (IBS). According to the manufacturer, these gastro-resistant capsules offer relief from abdominal discomfort, including bloating and cramps, particularly for individuals suffering from IBS. Each capsule contains 0.2ml of peppermint oil, which is equivalent to approximately 67 cups of peppermint tea, along with hyoscine butylbromide
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Type (Hyoscine Butyl Bromide and Hyoscine Hydrobromide), Application (Motion Sickness, Cramps, and Nausea), Route of Administration, (Intravenous, Oral, and Patches), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2031
.
The Global Hyoscine Market size was valued at USD 413.33 USD Million in 2023.
The Global Hyoscine Market is projected to grow at a CAGR of 3.8% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
